Skip to content

Optimization research on the comprehensive prevention and treatment scheme of diabetic nephropathy renal failure based on the shenluozhengjia theory.

Optimization research on the comprehensive prevention and treatment scheme of diabetic nephropathy renal failure based on the shenluozhengjia theory.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012681
Enrollment
Unknown
Registered
2017-09-15
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

tianjingtongluo group:tianjingtongluo decoction
xiaozhengsanjie group:xiaozhengsanjie decoction

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Being diagnosed diabetic kidney disease and meet the criteria for the staging of DKD renal failure in the subject; 2. Aged 25 to 65 years, male or female; 3. Have not received dialysis treatment; 4. Scr was relatively stable in 3 months ago for people who are chosen, with no change of over 15%; 5. for those with hypertesion, blood pressure should be control to less than 140/90mmHg, for people over 60 years old, the SBP should be less than150mmHg;Glycated hemoglobin (HbA1c) should be less than 7.0%; 6. HGB is at least higher than 110g/L (or by conventional Western Medicine treatment, HGB =110g/L); 7. subjects must be informed details of the trail and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Have severe infection or anemia, or electrolyte disorders, acute complications of diabetes in recent 4 weeks; 2. Have had serious heart, brain, liver or hemorrhage disease (like cerebral infarction, cerebral hemorrhage, transient ischemic attack, myocardial infarction, unstable angina, heart failureor result of ALT or AST is higher than 2 times of normal range and those who have been treated with corticosteroids or immunosuppressants in recent 3 month; 3. oliguria or anuria, severe edema, massive pleural and peritoneal effusion; 4. Have received renal transplantation; 5. Subjest with mental illness; 6. Women in gestational lactational period; 7. Allergic to the trial drugs; 8. Hepatitis B surface antigen positive; 9. Being enrolled to other clinical study; 10. not fully understand, reluctant to participant in, or do not sign informed consent.

Design outcomes

Primary

MeasureTime frame
24-hour urinary protein quantity;Scr;eGFR;

Secondary

MeasureTime frame
HGB;ALB;TCM syndrome;Quality of life;

Countries

China

Contacts

Public ContactYaoxian Wang

Dongzhimen Hospital, Beijing University of Chinese Medicine

wyx19660222@sina.com+86 010-84013229

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026